Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2000

View Archived Issues

AeroGen to develop inhaler device for cystic fibrosis agent

Oxigene and Techniclone join forces to develop new-generation anticancer agents

OvaRex shows evidence of cellular immune response

Amarillo Biosciences reports results of phase II trial of IFN-alpha in fibromyalgia

Pfizer and Warner-Lambert schedule shareholder meetings to consider merger

FDA approval sought for Imitrex in the treatment of adolescent migraine

CE Mark granted for the Prosorba Column as rheumatoid arthritis Rx

Ciba Vision seeks approval of Rescula on two continents for treatment of glaucoma

Santen presents new chymase inhibitors especially for cardiovascular disorders

Novel dihydropyrimidines from Merck are potent and selective alpha1A-adrenoceptor antagonists

New inhibitors of NOS, particularly iNOS, in early development at AstraZeneca

Tricyclic 5alpha-reductase inhibitors designed at Merck & Co.

Italian research institute searches for new enzyme-inhibitory antiviral agents

New compounds for cancer developed at Abbott

Back in the limelight: vasopeptidase inhibitor omapatrilat featured at ACC

Integrin receptor blockade assessed at DuPont for angiogenesis-mediated disorders

Bioglan Pharma and Sakai to jointly develop ES-Gel aciclovir formulation

Exochelin has potential in restenosis, according to data presented to the ACC

Neuromuscular blocking conopeptides evaluated in rat model; results reported at IARS congress

Synapse Technologies to work with VA on diagnostic for AD

Merger of three companies to create Genzyme Biosurgery

Alizyme receives notice of allowance, manufacturing license for mucositis product

Bivalirudin versus heparin during PTCA: six-month outcomes favor bivalirudin in post-MI patients

New treatment options for restenosis a hot topic at ACC

Detrusitol available in Spain for hyperactive bladder

Phase II study compares Vasoflux and heparin in AMI patients